IONTAS, a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells. The […]
Roche has received the US Food and Drug Administration (FDA) approval to use Tecentriq (atezolizumab) plus Abraxane and carboplatin chemotherapy to treat non-small cell lung cancer (NSCLC) patients. Approval is for adults with metastatic non-squamous […]
With IoT, eHealth, medical devices and technology revolutionising the pharmaceutical industry, SMi are pleased to announce that the inaugural Disruptive Technologies in Pharma conference will take place in London on the 20th-21st January 2020 and will […]
Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-EE, the Company’s pivotal Phase 3 clinical trial of vonoprazan for both the […]
SMi Reports: Co-chair interview released for SMi’s 4th Annual 3D Cell Culture 2020 taking place in London With SMi Group’s 3D Cell Culture returning for its 4th year on the 19th and 20th February 2020, […]